Hoechst Marion Roussel Funds Outcomes Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grants totaling nearly $500,000 to fund health economics and outcomes studies through its 1997 ACCORD (A Company-wide Commitment to Outcomes Research and Development) program.

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grantstotaling nearly $500,000 to fund health economics and outcomes studiesthrough its 1997 ACCORD (A Company-wide Commitment to Outcomes Researchand Development) program.

Researchers and institutions interested in applying for grants can receivea program brochure and application form by calling ACCORD coordinator MaryMiller at 816-966-3780. The deadline for proposals is August 15, 1997.

Articles in this issue
Studies of Counselings' Impact on Survival Challenged
Telomerase Activity Potential Marker for Bladder Cancer
HIV Has Become a Specialty Disease, But One Open to the Well-Informed Generalist
Writing Genetic Testing Guidelines Complex Endeavor
AACR Meeting Sees Growth Spurt in Telomerase Research
DDT Appears to Activate Human Estrogen Receptors
Studies Highlight Role of bcl-2 Gene in Programmed Cell Death
Efficacy of BCG Maintenance in Bladder Cancer Is Confirmed
Surgery Seen as Adjunct to Chemo in Some Invasive Breast Cancers
Traveling Exhibit of Cancer Educational Resources
History of Substance Abuse Not a Barrier to Opioid Use
Support Program for Melanoma Patients Receiving Interferon
Taxol/Adriamycin as First-Line Metastatic Breast Cancer Therapy
New Cancer Websites, New Features Join the Information Highway
Dying in Hospital May Be Preferable to Dying at Home

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
6371178759112
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Related Content
Promoting Psychosocial Cancer Care on World Psycho-Oncology Day

Promoting Psychosocial Cancer Care on World Psycho-Oncology Day

Tim Cortese
April 9th 2025
Article

The International Psycho-Oncology Society announced the first ever WPOD on April 9, 2025, to bring more focus to psychosocial care in cancer therapy.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Combining durvalumab with chemotherapy produced a good safety profile without increasing surgical risk in the phase 2 iNDUCT-GETUG V08 trial.

Durvalumab Combo Shows Encouraging Preliminary Data in High-Risk UTUC

Russ Conroy
April 8th 2025
Article

Combining durvalumab with chemotherapy produced a good safety profile without increasing surgical risk in the phase 2 iNDUCT-GETUG V08 trial.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025
Podcast

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC

FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC

Tim Cortese
April 8th 2025
Article

The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.

PENELOPE-B Trial Shows Mixed Palbociclib Results in Breast Cancer Subtypes

PENELOPE-B Trial Shows Mixed Palbociclib Results in Breast Cancer Subtypes

Tim Cortese
April 8th 2025
Article

Palbociclib with endocrine therapy did not improve outcomes in HR-positive, HER2-negative breast cancer, but improved invasive DFS in lobular disease.